Leading Chinese CRO WuXi PharmaTech Aims To Ensure Rebound After 2008's Massive Loss With Launch Of New Toxicology Center
This article was originally published in PharmAsia News
Executive Summary
BEIJING - To solidify a recovery after posting a massive loss for last year, WuXi PharmaTech is pumping funds into a new drug safety testing center and state-of-the-art manufacturing facility along the economically dynamic East coast of China
You may also be interested in...
WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
BEIJING - The leadership of WuXi PharmaTech, China's top contract research organization, has spelled out for the first time in detail how its ill-timed acquisition of an American biologics manufacturing and testing outfit, lashed by the tempests of the West's financial crisis, triggered a massive loss that wiped out five years of earnings
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).